Thus, candidates should be tested against a panel of receptors at the time of antibody engineering. ACROBiosystems provides an extensive collection of recombinant Fc receptor proteins, which ...

antibody. CF patients, chronic pulmonary disease patients and hypogammaglobulinemics had accelerated Fc receptor mediated clearance rates (T 1/2 =19.6 min, 16 min and 12.8 min, respectively ...

ACROBiosystems has designed high-quality target antigen proteins and Fc receptor proteins to enable biosimilar research. ACROBiosystems strictly ensures the quality to deliver products with ...

Phase III Vivacity-MG3 trial shows that nipocalimab, an investigational FcRn blocker, significantly the improves symptoms of generalized myasthenia gravis with a manageable safety profile.

In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent ...

The therapeutic antibody industry has been propelled by ... Kenneth Smith and Menna Clatworthy describe the role of the only inhibitory Fc receptor for IgG (FcγRIIB) in autoimmunity and infection ...

Argenx only recently scored FDA approval for its intravenous anti-neonatal FC receptor (FcRn) antibody Vyvgart for generalised myasthenia gravis (gMG), but is already looking to defend its ...

They also found that an existing monoclonal antibody binding to this protein ... produce proteins that combine to form the ...

Johnson & Johnson JNJ announced that the FDA has accepted its regulatory filing seeking the FDA’s approval for nipocalimab, its investigational neonatal Fc receptor (FcRn) blocker, in ...